Renewal Of Marketing Authorisation, The Mutual Recognition Secondoprocedura, Of The Medicinal Product For Human Use "nebivolol Teva Italy», Resulting In A Review Printed.

Original Language Title: Rinnovo dell'autorizzazione all'immissione in commercio, secondoprocedura di mutuo riconoscimento, del medicinale per uso umano«Nebivololo Teva Italia», con conseguente modifica stampati.

Read the untranslated law here: http://www.gazzettaufficiale.it/atto/serie_generale/caricaArticoloDefault/originario?atto.dataPubblicazioneGazzetta=2015-01-12&atto.codiceRedazionale=15A00075&elenco30giorni=false&atto.tipoProvvedimento=DECRETO

Retrieved December 16, 2014 # PV 406/2014 of Medicine determines: NEBIVOLOL TEVA ITALY packaging: 040028 019 "5 mg tablets" 7 tablets in PVC/PVDC/aluminium 040028 021 "5 mg tablets" 8 tablets in PVC/PVDC/aluminium 040028 033 "5 mg tablets" 10 tablets in PVC/PVDC/aluminium 040028 045 "5 mg tablets" 14 tablets in PVC/PVDC/aluminium 040028 058 "5 mg tablets" 15 tablets in PVC/PVDC/aluminium 040028 060 "5 mg tablets" 20 tablets in PVC/PVDC/aluminium 040028 072 "5 mg tablets" 28 tablets in PVC/PVDC/aluminium 040028 084 "5 mg tablets" 30 tablets in PVC/PVDC/aluminium 5 mg tablet "50" 040028 096 tablets in PVC/PVDC/aluminium 040028 108 "5 mg tablets" 56 tablets in PVC/PVDC/aluminium 5 mg tablet "60" 040028 110 tablets in PVC/PVDC/90 tablets 5 mg tablet "040028 122" in PVC/PVDC/AL 040028 134 "5 mg tablets" 98 tablets in PVC/PVDC/per 100 tablets 5 mg tablet "040028 146" in PVC/PVDC/aluminium 040028 159 "5 mg tablets" 500 tablets in PVC/PVDC/aluminium 5 mg tablet "50" 040028 161 tablets in single-dose PVC/PVDC/bulk package Mah: TEVA ITALIA S.R.L. Mutual recognition procedure HU/H/0184/001/R/001 expiring on May 31, 2012 is renewed, with unlimited validity, the marketing authorisation subject to amendment of the summary of product characteristics, package leaflet and labelling and on condition that, on the date of entry into force of this determination, the requirements of quality, safety and efficacy are still present.
Changes must be made immediately to the summary of the product characteristics as per the package leaflet and labelling no later than six months after its publication in the Official Gazette of the Italian Republic of this determination.
In accordance with art. 80, paragraphs 1 and 3, of Legislative Decree No 219 April 24, 2006 and s leaflet and labels must be written in Italian and, limited to medicinal products marketed in the province of Bolzano, in German. The mAh avails itself of the complementary use of foreign languages, must give prior notice to the AIFA and keep available the certified translation of German texts and/or in another foreign language. In case of non-compliance with the provisions on the labelling and package leaflet shall apply sanctions under art. 82 of the Decree.
Both lots already products as of the date of publication in the official journal of the Italian Republic of this determination that the batches produced during the period referred to in art. 2, paragraph 2, of the aforementioned determination, which did not indicate the changes authorized, can be kept on the market until the expiration date printed on the label of the medicine. Pharmacists are required to deliver the package leaflet updated users as from the end of 30 days from the date of publication in the Official Gazette of the Italian Republic of this determination. The mAh makes accessible to pharmacist leaflet updated within the same timeframe.
This determination takes effect from the day following that of its publication in the official journal of the Italian Republic and will be notified to the company holder of the marketing authorisation of the medicinal product.